Louisville CyberKnife Radiation Oncologist Discusses CyberKnife Treatment for Prostate Cancer on WAVE 3 Listens Live

 

Louisville CyberKnife radiation oncologist Dr. Neal Dunlap shared the benefits of CyberKnife® treatment for prostate cancer on “WAVE 3 Listens Live.” See a full video of the interview below.

 

Learn More

 

 

ASTRO Endorses Stereotactic Body Radiation Therapy As First-Line Prostate Cancer Treatment Option

 

The American Society for Radiation Oncology has announced the classification of stereotactic body radiation therapy as a first-line treatment option for prostate cancer. As a first-line treatment, SBRT can be considered a primary form of treatment for prostate cancer. The results of long-term clinical trials supporting the safety and efficacy of stereotactic body radiation in […]

 

Learn More

 

 

Louisville CyberKnife Discusses Brain Tumors on WAVE 3 Listens Live

 

Louisville CyberKnife radiation oncologist Dr. Anthony Dragun discussed the benefits of CyberKnife® technology in treating brain and spinal tumors on “WAVE 3 Listens Live.”

 

Learn More

 

 

Louisville CyberKnife Radiation Oncologists on WHAS Great Day Live

 

Louisville CyberKnife radiation oncologists Dr. Moataz El-Ghamry and Dr. Neal Dunlap explain the benefits of CyberKnife® treatment for prostate and lung cancer on WHAS-TV’s “Great Day Live.”

 

Learn More

 

 

Louisville CyberKnife Offers Prostate Cancer Patients Advanced Form of Radiation Therapy

 

According to the American Cancer Society, prostate cancer will account for an estimated 13 percent of total cancer diagnoses in Kentucky this year. Men in central Kentucky and southern Indiana facing a prostate cancer diagnosis and seeking treatment can now add a new option to the list “Ó CyberKnife®. In the fall of 2012, the […]

 

Learn More

 

 

Louisville CyberKnife on WAVE Listens Live

 

Louisville CyberKnife’s medical director Dr. Shiao Woo appeared on “WAVE Listens Live” to discuss CyberKnife’s noninvasive treatment of tumors throughout the body.

 

Learn More